BMIKorea
- Biotech or pharma, therapeutic R&D
BMI Korea, established in 2005, is a South Korean biopharmaceutical company focusing on the development and commercialization of new medicines, including biologics, and medical devices. BMI seeks business partnerships for licensing Recombinant Hyaluronidase, an enabling enzyme that facilitates the conversion of intravenous (IV) biologic drugs into subcutaneous (SC) formulations, thereby enhancing patient convenience and treatment accessibility.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}